Dual PPARα/γ Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice - Concepedia

Concepedia

Publication | Open Access

Dual PPARα/γ Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice

DOI Full Paper Access

47

Citations

41

References

2006

Year

A. Susanne M. Zadelaar, Lianne S.M. Boesten, J. Wouter Jukema, Bart J.M. van Vlijmen, Teake Kooistra, J.J. Emeis, Erik Lundholm, Germán Camejo, Louis M. Havekes

Arteriosclerosis Thrombosis and Vascular Biology

Abstract

Tesaglitazar has anti-atherosclerotic effects in the mouse model that go beyond plasma cholesterol lowering, possibly caused by a combination of altered lipoprotein profiles and anti-inflammatory vascular effects.

References

	Year	Citations

Page 1